Many studies have established that systemic and long‐term antitumor immunity depends mainly on the establishment of memory CD8+ T cells.[27] As shown in Figure S24a,b (Supporting Information), the proportions of both CD3+CD8+ T cells and CD44+CD62L‐ effector memory CD8+ T cells (Tem) were significantly elevated after N@VP + 2 Gy treatment in tumor microenvironment. Here, CD44 is linked to neoplasm.